Skip to main content

Peer Review reports

From: MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

Original Submission
8 Jan 2009 Submitted Original manuscript
5 Feb 2009 Reviewed Reviewer Report - Shan Lu
13 Mar 2009 Reviewed Reviewer Report - Juan Carlos Prieto
Resubmission - Version 2
Submitted Manuscript version 2
31 Mar 2009 Author responded Author comments - wenqing Qi
Resubmission - Version 3
31 Mar 2009 Submitted Manuscript version 3
7 May 2009 Author responded Author comments - wenqing Qi
Resubmission - Version 4
7 May 2009 Submitted Manuscript version 4
Publishing
11 May 2009 Editorially accepted
11 May 2009 Article published 10.1186/1471-2407-9-142

You can find further information about peer review here.

Back to article page